| Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch | Frank Vinluan | 02/14/20 | New York |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come | Frank Vinluan | 02/10/20 | New York |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup | Frank Vinluan | 02/04/20 | New York |
| Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic | Sarah de Crescenzo | 02/03/20 | New York |
| Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals | Sarah de Crescenzo | 02/03/20 | New York |
| Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony” | Dan Stanton | 02/03/20 | New York |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins | Sarah de Crescenzo | 01/29/20 | New York |
| Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus | Frank Vinluan | 01/29/20 | Boston |
| Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets | Sarah de Crescenzo | 01/28/20 | San Diego |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune | Mike Ward | 01/23/20 | National |
| Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits | Frank Vinluan | 01/22/20 | New York |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D | Frank Vinluan | 01/15/20 | New York |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Schrödinger Sets Course for IPO to Support Growing Internal Pipeline | Frank Vinluan | 01/14/20 | New York |
| Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial | Sarah de Crescenzo | 01/13/20 | San Francisco |
